Wanda Knopińska‐Posłuszny

Author

Also Known As

Knopińska-Posłuszny, Wanda, M Hus, Michal Taszner, W Knopinska-Posluszny, W Knopińska-Posłuszny, W. Knopinska-Posluszny, W. Knopińska-Posłuszny, W. Knopińska-posłuszny, W. Knopińska‐Posłuszny, WANDA KNOPINSKA-POSLUSZNY

108

Publications

Citations

H-Index

Concepts

All Affiliations

Gdańsk Medical University The Maria Sklodowska-Curie National Research Institute of Oncology Jagiellonian University Medical University of Silesia Medical University of Warsaw

About

Wanda Knopińska‐Posłuszny is an author at Gdańsk Medical University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	232
2	Health Sciences	3	3	68
3	Public Health	1	1	19
4	Allergy	1	1	10
5	Allergy Medicine	1	1	10

Wanda Knopińska‐Posłuszny

Publications

802

Citations

H-Index

Page 1

	Year	Citations
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Journal of Clinical Oncology	2021	151
Uncontrolled‐rate freezing and storage at –80°C, with only3.5‐percent DMSO in cryoprotective solution for 109 autologous peripheral blood progenitor cell transplantations Pascale Halle, Olivier Tournilhac, Wanda Knopińska‐Posłuszny, Transfusion	2001	103
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients Artur Jurczyszyn, Jakub Radocha, Julio Dávila, British Journal of Haematology	2018	67
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen — A national multicenter study Wojciech Jurczak, Sebastian Szmit, Marcin Sobociński, International Journal of Cardiology Lymphoid NeoplasiaCardiovascular DiseaseMedicinePremature Cardiovascular MortalityNational Multicenter Study	2013	52
Characteristics and outcomes of patients with multiple myeloma aged 21–40 years versus 41–60 years: a multi‐institutional case‐control study Artur Jurczyszyn, Hareth Nahi, Irit Avivi, British Journal of Haematology	2016	40
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG) Elżbieta Iskierka‐Jazdzewska, Marek Hus, Krzysztof Giannopoulos, Leukemia & lymphoma/Leukemia and lymphoma Clinical EndpointPharmacotherapyAdverse Drug ReactionHematological MalignancyOncology	2017	39
Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience Grzegorz Basak, Wanda Knopińska‐Posłuszny, Magdalena Matuszak, Annals of Hematology	2010	37
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy Jarosław Czyż, Richard Szydlo, Wanda Knopińska‐Posłuszny, Bone Marrow Transplantation Surgical OncologyMedicineTreatment OptionHigh-dose ChemotherapyMetronomic Chemotherapy	2004	25
First‐line R‐CVP <i>versus</i> R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4 Jan Walewski, Ewa Paszkiewicz‐Kozik, Wojciech Michalski, British Journal of Haematology	2019	25
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma Aleksander Salomon‐Perzyński, Adam Walter‐Croneck, Lidia Usnarska‐Zubkiewicz, Advances in Medical Sciences Hematological MalignancyOncologyDaratumumab MonotherapyImmunologyHematology	2019	24

Page 1